Full Prescribing Info
Dosage/Direction for Use

Short-term management of severe heart failure, Acutely decompensated heart failure
Adult: Initially, a loading dose of 50 mcg/kg by slow IV injection over 10 min then continuous maintenance infusion of 0.375-0.75 mcg/kg/min. Adjust according to haemodynamics and clinical response. Max dose 1.13 mcg/kg/day.
Child: Initial loading dose of 75 mcg/kg by IV injection over 10-60 min followed by continuous infusion of 0.5-0.75 mcg/kg/min.
Renal impairment:
CrCl (ml/min)Dosage Recommendation
500.43 mcg/kg/min
400.38 mcg/kg/min
300.33 mcg/kg/min
200.28 mcg/kg/min
100.23 mcg/kg/min
50.20 mcg/kg/min
Heart valve stenosis, acute myocardial infarction.
Special Precautions
Severe obstructive aortic or pulmonary valvular disease, hypertrophic cardiomyopathy, atrial flutter or fibrillation. Monitor blood pressure, heart rate, ECG, fluid and electrolyte balance. Pregnancy and lactation. Use for >48 hr.
Adverse Reactions
Angina-like chest pain, headache, hypokalaemia, tremor, thrombocytopenia, bronchospasm.
Potentially Fatal: Supraventricular and ventricular arrhythmias; hypotension.
Milrinone is a selective phosphodiesterase III inhibitor with positive inotropic and vasodilator activity. It selectively inhibits cyclic adenosine monophosphate (cAMP) phosphodiesterase activity in cardiac and vascular muscles resulting in increased intracellular concentrations of cAMP. It also acts directly on vascular smooth muscle.
Onset: IV: 5-15 minutes.
Distribution: Protein binding: About 70%. Volume of distribution at steady-state: 0.32-0.45 L/kg.
Metabolism: About 12% metabolised hepatically.
Excretion: Eliminated via urine (85% as unchanged drug). Elimination half life: About 2.5 hr.
Intravenous: Store at 15-30°C.
CIMS Class
ATC Classification
C01CE02 - milrinone ; Belongs to the class of phosphodiesterase inhibitors. Used in the treatment of heart failure.
Disclaimer: This information is independently developed by CIMS based on milrinone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in